There are many overall benefits of decentralized, hybrid trials and remote monitoring
TORONTO (PRWEB) May 19, 2020
Historically, the clinical research community has been slow to adopt decentralized or hybrid trial models. There are many overall benefits of decentralized, hybrid trials and remote monitoring: increased enrollment and retention of patients in clinical studies, the reduction of administrative burdens on sponsors and investigators, and the ability for patients to receive treatments from their community providers without compromising study quality or data integrity.
The COVID-19 pandemic has made these benefits even more obvious, and as travel restrictions, social distancing, and the overall strain on the healthcare system became more evident, the FDA updated regulations to fast-track research, openly recognizing the value of alternative technology such as virtual trial capabilities in clinical research.
Join Eli Alford, MS, Chief Operating Officer at Elligo Health Research in a live webinar on Thursday, June 4, 2020 at 1pm EDT in which he will share how Elligo’s healthcare-enabling approach was able to respond rapidly to the challenges presented by COVID-19 by effectively supporting and staffing drive-thru COVID-19 test sites while also maintaining support for active trials across their network.
For more information or to register for this event, visit Continuing Clinical Research Innovations After COVID-19.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.